Data as of Q4 2025 (Dec 31, 2025)

ROCKET PHARMACEUTICALS, INC.

(RCKT)

Financial Statements · SEC EDGAR XBRL

Revenue
$0
Net Income
-$223.1M
+13.8%
EPS
$-2.01
+26.4%
Op. Income
-$231.7M
+15.2%
FCF
-$190.5M
+11.7%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$142.0M
$171.2M
$186.3M
$165.6M
$125.5M
$231.7M
$273.2M
$259.7M
$224.3M
$167.2M
-$231.7M
-$273.2M
-$259.7M
-$224.3M
-$167.2M
$1.9M
$1.9M
$1.9M
$1.9M
$3.0M
-
-
-
$2.5M
-$1.8M
-$223.1M
-$258.7M
-
-
-
$0
$0
$0
-
-
-$223.1M
-$258.7M
-$245.6M
-$221.9M
-$169.1M
$-2.01
$-2.73
$-2.92
$-3.26
$-2.67
$-2.01
$-2.73
$-2.92
$-3.26
$-2.67